What is it about?
In clinical trials, the severity of IBD (Crohn's and Colitis) is determined by what the patient reports and what the colonoscopy shows. There are many steps from scheduling the patient, selecting the right bowel prep, recording the videos, using a scoring system, combining the assessment of several different physicians who look at the same video, training, and quality assurance that may at present be suboptimal but which can be improved.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
This paper combines the collective wisdom of six industry and six academic experts in the field of IBD and clinical trial design and conduct. Many recommendations can be immediately implemented to make Inflammatory Bowel Disease clinical trials more successful.
Perspectives
Artificial Intelligence that tries to predict what a human reader would say about a colonoscopy video, i.e., the disease severity score, must be trained on ‘gold standard’ data. This paper shows how we can achieve more reliable and higher quality results with our human readers, who, however variable their judgment may be, are our current ground truth.
Klaus Gottlieb
Eli Lilly and Co
Read the Original
This page is a summary of: Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments, Gut, July 2020, BMJ,
DOI: 10.1136/gutjnl-2020-320690.
You can read the full text:
Contributors
The following have contributed to this page
